Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States and internationally. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
IPO Year: 2014
Exchange: NASDAQ
Website: sientra.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/14/2022 | $8.00 | Buy | Lake Street |
IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022
IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million in the prior year period. Third quarter results were adversely affected by overall softness in the market as well as more pronounced seasonal headwinds that led to a reduced number of augmentation and reconstru
Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement inoperating cash flow and adjusted EBITDA respectively Continued success in advancing products through the FDA regulatory process with clearance of Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the second quarter tha
IRVINE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN)("Sientra" or the "Company"), a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced that it will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time. The dial-in numbers are (844) 735-3763 for domestic callers and (412) 317-5711 for international callers. A live webcast of the conference call will be available on the Investor Relations section of the Company's website
IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eleventh consecutive quarter of year-over-year growth, fueled by market outperformance in reconstruction Continued improvement in non-GAAP OPEX, adjusted EBITDA, and free cash flow performance demonstrating clear pathway to profitability Doubled total addressable market in the United States with commercial launch of Viality™ and SimpliDerm® ADM partnership Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced its financial results for the first quarter that ended March 31, 2023. First Quarter 2023 Financial and Business Hi
IRVINE, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Thursday, May 11, 2023. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time. The dial-in numbers are (877) 270-2148 for domestic callers and (412) 902-6510 for international callers. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The web
Continued 2+ year trend of consecutive record quarterly growth; fastest growing brand in the US breast market Disciplined cash management and enhanced operating leverage for 40% improvement in free cash flow results Significantly increased total addressable market with the launch of Viality™, a novel, FDA-cleared fat transfer technology, and addition of SimpliDerm®, a leading human Acellular Dermal Matrix (ADM) IRVINE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced its financial results for the fourth quarter and full year
IRVINE, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Thursday, March 30, 2023. Sientra will host a conference call to discuss financial results the same day at 4:00 p.m. Eastern Time. The dial-in numbers are (877) 270-2148 for domestic callers and (412) 902-6510 for international callers. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.s
SANTA BARBARA, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced its financial results for the third quarter that ended September 30, 2022. Q3 2022 Financial and Business Highlights Net sales of $22.6 million, representing growth of 15% over the third quarter of 2021Year-to-date net sales of $65.5 million, representing growth of nearly 13% compared to the same period of 2021Reduced free cash outflow to a record low of $3.6 millionAdded 130 new augmentation accounts, and 160 new reconstruction accountsReceived approval of Sientr
SANTA BARBARA, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 10, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time. The dial-in numbers are 1-866-374-5140 for domestic callers. The conference ID is 57765123#. The webcast link is the following: Sientra Q3' 2022 Earnings Call Webcast Registration Link. A live webcast of the conference call will be ava
Lake Street initiated coverage of Sientra with a rating of Buy and set a new price target of $8.00
Canaccord Genuity reiterated coverage of Sientra with a rating of Buy and set a new price target of $10.00 from $9.00 previously
SVB Leerink reiterated coverage of Sientra with a rating of Outperform and set a new price target of $11.00 from $10.00 previously
Canaccord Genuity reiterated coverage of Sientra with a rating of Buy and set a new price target of $9.00 from $8.00 previously
SVB Leerink reiterated coverage of Sientra with a rating of Outperform and set a new price target of $10.00 from $8.00 previously
Maxim Group resumed coverage of Sientra with a rating of Buy and set a new price target of $11.00
Canaccord Genuity reiterated coverage of Sientra with a rating of Buy and set a new price target of $8.00 from $6.00 previously
Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra's breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra's BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. ("Sientra" or the "Company") announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC ("Tiger") has been declared the successful bidder for certain of the assets of Sientra used in its breast reconstruction and augmentation business. As consideration for the acquisition, Tiger will pay a cash consid
IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. The Company seeks to execute an expedited sale process. Sientra will utilize existing cash reserves and $22.5 million in new money d
IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022
IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its participation at the Stifel 2023 Healthcare Conference. As part of the conference, the company's management team will participate in a live fireside chat on Wednesday, November 15, 2023 at 8:00am EST / 5:00am PST. An on-demand webcast of the presentation will be accessible under "News & Events" in the Investors section of the company's website at www.sientra.com. A replay of the webcast will be available on the Sientra website for 90 days following t
IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million in the prior year period. Third quarter results were adversely affected by overall softness in the market as well as more pronounced seasonal headwinds that led to a reduced number of augmentation and reconstru
Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement inoperating cash flow and adjusted EBITDA respectively Continued success in advancing products through the FDA regulatory process with clearance of Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the second quarter tha
IRVINE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN)("Sientra" or the "Company"), a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced that it will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time. The dial-in numbers are (844) 735-3763 for domestic callers and (412) 317-5711 for international callers. A live webcast of the conference call will be available on the Investor Relations section of the Company's website
DALLAS, July 17, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower partners. "During the second quarter of 2023 SWK advanced our 2023 objectives including securing a new four-year credit facility with First Horizon Bank with $45 million committed at close," stated Jody Staggs, President and CEO of SWK. "This credit facility enables us
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced that on June 27, 2023, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 20 new employees. The new employees were granted restricted stock units representing a total of 85,750 shares of common stock. The restricted stock units will vest in time-based installments beginning on the grant date. In each case, the vesting of shares is contingent upon the recipient's continued service with the Company through each vesting date. The grants were made as an inducement that
IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company's Board of Directors, effective June 15, 2023. "On the heels of no less than 3 new product approvals in the United States in the past 12 months, and with continued strong topline performance and a near-term path to profitability, we are delighted to welcome Alex to the Sientra Board of Directors," said Caro Van Hove, Executive Chair of Sientra. "With Kevin O'Boyle retiring from the Board after nearly a decade of exceptional
4 - Sientra, Inc. (0001551693) (Issuer)
4 - Sientra, Inc. (0001551693) (Issuer)
4 - Sientra, Inc. (0001551693) (Issuer)
4 - Sientra, Inc. (0001551693) (Issuer)
4 - Sientra, Inc. (0001551693) (Issuer)
4 - Sientra, Inc. (0001551693) (Issuer)
4 - Sientra, Inc. (0001551693) (Issuer)
4 - Sientra, Inc. (0001551693) (Issuer)
4 - Sientra, Inc. (0001551693) (Issuer)
3 - Sientra, Inc. (0001551693) (Issuer)
IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company's Board of Directors, effective June 15, 2023. "On the heels of no less than 3 new product approvals in the United States in the past 12 months, and with continued strong topline performance and a near-term path to profitability, we are delighted to welcome Alex to the Sientra Board of Directors," said Caro Van Hove, Executive Chair of Sientra. "With Kevin O'Boyle retiring from the Board after nearly a decade of exceptional
SANTA BARBARA, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Dr. Irina Erenburg and Nori Ebersole to its Board of Directors effective July 16, 2021. "We are extremely pleased to welcome Irina and Nori to the Sientra Board," said Caroline Van Hove, Executive Chairwoman of Sientra. "Irina and Nori's deep respective experiences and competencies in building disruptive R&D engines and best-in-class organizations in Medical Aesthetics will significantly contribute to Sientra's high-growth strategy and our singular focus to be the number one
SANTA BARBARA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Andy Schmidt has been appointed Chief Financial Officer (CFO) effective immediately. As a key member of Sientra's executive leadership team, Mr. Schmidt will lead the Company's financial operations. "We are extremely pleased to welcome a strong leader like Andy to the Sientra team. His experience with growth-oriented public companies will be invaluable as we work towards expanding our market share and advancing the art of plastic surgery," said Ron Menezes, President and Chief Executive Of
SANTA BARBARA, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Denise Dajles as Vice President of Research & Development, effective today. In this new role, Ms. Dajles will report to Chief Executive Officer Ron Menezes and lead Sientra's R&D and medical affairs teams. "We are pleased to welcome Denise to the Sientra management team," said Ron Menezes, President and CEO of Sientra. "With her considerable technical and international expertise, Denise is well-suited to lead our R&D organization as we pursue our goal to be the leader in br
SANTA BARBARA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Paul Little is stepping down from his position as Chief Financial Officer, Senior Vice President and Treasurer, to pursue other opportunities effective March 12, 2021. Valerie Miller, current Vice President, Corporate Controller, will serve as interim Chief Financial Officer effective upon Mr. Little’s resignation as the Company completes its search for a permanent replacement. “We thank Paul for his diligent work and greatly appreciate all his contributions to our team through his tenur
8-K - Sientra, Inc. (0001551693) (Filer)
8-K - Sientra, Inc. (0001551693) (Filer)
8-K - Sientra, Inc. (0001551693) (Filer)
8-K - Sientra, Inc. (0001551693) (Filer)
8-K - Sientra, Inc. (0001551693) (Filer)
10-Q - Sientra, Inc. (0001551693) (Filer)
8-K - Sientra, Inc. (0001551693) (Filer)
8-K - Sientra, Inc. (0001551693) (Filer)
10-Q - Sientra, Inc. (0001551693) (Filer)
8-K - Sientra, Inc. (0001551693) (Filer)
SC 13G/A - Sientra, Inc. (0001551693) (Subject)
SC 13G - Sientra, Inc. (0001551693) (Subject)
SC 13G - Sientra, Inc. (0001551693) (Subject)
SC 13G/A - Sientra, Inc. (0001551693) (Subject)
SC 13G/A - Sientra, Inc. (0001551693) (Subject)
SC 13D - Sientra, Inc. (0001551693) (Subject)
SC 13G - Sientra, Inc. (0001551693) (Subject)
SC 13D/A - Sientra, Inc. (0001551693) (Subject)
SC 13G - Sientra, Inc. (0001551693) (Subject)
SC 13G - Sientra, Inc. (0001551693) (Subject)
Shares of Fluor Corporation (NYSE:FLR) fell during Tuesday’s session following fourth-quarter results. Fluor posted adjusted earnings of 68 cents per share, beating market estimates of 57 cents per share. The company’s quarterly sales came in at $3.82 billion versus expectations of $4.11 billion. Fluor shares declined 7.7% to $38.84 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers TRxADE HEALTH, Inc. (NASDAQ:MEDS) shares jumped 214% to $13.00. TRxADE HEALTH announced the sale of assets of subsidiary Trxade, Inc. to Micro Merchant Systems for $22.5 million, with potential additional $7.5 million payout. AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) sur
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares rose 138.8% to $0.82 during Tuesday's regular session. The market value of their outstanding shares is at $12.1 million. Trxade Health (NASDAQ:MEDS) shares rose 86.05% to $8.54. The market value of their outstanding shares is at $10.2 million. Biofrontera (NASDAQ:BFRI) shares rose 67.04% to $1.25. The company's market cap stands at $2.1 million. Iovance Biotherapeutics (NASDAQ:IOVA) shares increased by 39.12% to $12.73. The company's market cap stands at $3.2 billion. SeaStar Medical Holding (NASDAQ:ICU) stock rose 22.32% to $1.42. The market value of their outstanding shares is at $92.4 million. Gossamer Bio (NASDAQ:GOSS) shares increa
Gainers Trxade Health (NASDAQ:MEDS) shares rose 207.2% to $14.1 during Tuesday's pre-market session. The company's market cap stands at $16.9 million. Biofrontera (NASDAQ:BFRI) stock moved upwards by 206.87% to $2.3. The company's market cap stands at $3.8 million. Monopar Therapeutics (NASDAQ:MNPR) stock rose 43.89% to $0.49. The market value of their outstanding shares is at $7.3 million. Tharimmune (NASDAQ:THAR) stock rose 31.82% to $0.51. The market value of their outstanding shares is at $1.2 million. Ocugen (NASDAQ:OCGN) stock increased by 28.54% to $1.22. The company's market cap stands at $312.9 million. Iovance Biotherapeutics (NASDAQ:IOVA) shares rose 20.0% to $10.98. The com
Gainers Trxade Health (NASDAQ:MEDS) stock rose 105.3% to $8.5 during Monday's after-market session. The company's market cap stands at $10.2 million. Iovance Biotherapeutics (NASDAQ:IOVA) shares moved upwards by 32.78% to $12.15. The company's market cap stands at $3.1 billion. Virpax Pharmaceuticals (NASDAQ:VRPX) shares moved upwards by 13.29% to $0.37. The company's market cap stands at $4.3 million. Delcath Systems (NASDAQ:DCTH) shares increased by 9.92% to $4.84. The market value of their outstanding shares is at $106.6 million. Dyadic International (NASDAQ:DYAI) shares moved upwards by 9.84% to $1.45. The company's market cap stands at $41.7 million. NexImmune (NASDAQ:NEXI) stock
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 25.2% to $2.73 during Friday's pre-market session. The company's market cap stands at $1.5 million. MediciNova (NASDAQ:MNOV) stock increased by 17.77% to $1.59. The market value of their outstanding shares is at $77.9 million. As per the press release, Q4 earnings came out yesterday. Sarepta Therapeutics (NASDAQ:SRPT) shares moved upwards by 14.5% to $143.0. The market value of their outstanding shares is at $13.3 billion. Ikena Oncology (NASDAQ:IKNA) shares rose 12.32% to $1.64. The company's market cap stands at $79.1 million. Sientra (NASDAQ:SIEN) stock increased by 11.4% to $0.38. The company's market cap stands at $
Gainers Sientra (NASDAQ:SIEN) stock rose 193.5% to $0.53 during Thursday's regular session. The market value of their outstanding shares is at $6.3 million. Hepion Pharmaceuticals (NASDAQ:HEPA) stock increased by 28.78% to $2.55. The market value of their outstanding shares is at $11.0 million. Orgenesis (NASDAQ:ORGS) stock increased by 23.78% to $0.42. The company's market cap stands at $13.4 million. Inspire Veterinary (NASDAQ:IVP) stock rose 23.1% to $0.14. The company's market cap stands at $3.9 million. Inogen (NASDAQ:INGN) stock increased by 20.44% to $10.25. The market value of their outstanding shares is at $238.9 million. American Well (NYSE:AMWL) shares rose 18.91% to $1.32.